In a research report issued today, William Blair analyst Y Katherine Xu maintained an Outperform rating on Ariad Pharmaceuticals (NASDAQ:ARIA) with a $12 price …
In a research report released today, H.C.
Ariad Pharmaceuticals (ARIA) had its price target reduced by UBS from $7.50 to $7.
